Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Leukemia Research

Volumn 39, Issue 12, 2015, Pages 1367-1374

  Badar, Talha ^a   Patel, Keyur P ^a   Thompson, Philip A ^a   DiNardo, Courtney ^a   Takahashi, Koichi ^a   Cabrero, Monica ^a   Borthakur, Gautam ^a   Cortes, Jorge ^a   Konopleva, Marina ^a   Kadia, Tapan ^a   Bohannan, Zach ^a   Pierce, Sherry ^a   Jabbour, Elias J ^a   Ravandi, Farhad ^a   Daver, Naval ^a   Luthra, Raja ^a   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AML; FLT3 ITD; Leukemic transformation; MDS; RAS

Indexed keywords

ANTHRACYCLINE; AZACITIDINE; CD135 ANTIGEN; CLADARABINE; CLOFARABINE; CYTARABINE; DECITABINE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; LENALIDOMIDE; NUCLEOSIDE DERIVATIVE; RAS PROTEIN; THALIDOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CODON; FLT3 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE DURATION; DRUG TREATMENT FAILURE; FLT3 ITD GENE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; ONCOGENE RAS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; WILD TYPE; CELL TRANSFORMATION; CODON; DISEASE COURSE; FEMALE; GENETICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TANDEM REPEAT; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL TRANSFORMATION, NEOPLASTIC; CODON; DISEASE PROGRESSION; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TANDEM REPEAT SEQUENCES; TREATMENT OUTCOME;

EID: 84961711374     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2015.10.005     Document Type: Article

References (37)

1. Greenberg P.L., Tuechler H., Schanz J., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120(12):2454-2465.
2. Walter M.J., Shen D., Ding L., et al. Clonal architecture of secondary acute myeloid leukemia. New Engl. J. Med. 2012, 366(12):1090-1098.
3. Haferlach C., Zenger M., Alpermann T., Schnittger S., Kern W., Haferlach T. Cytogenetic clonal evolution in MDS is associated with shifts towards unfavorable karyotypes according to IPSS and shorter overall survival: a study on 988 MDS patients studied sequentially by chromosome banding analysis. ASH Annu. Meeting Abstr. 2011.
4. Jabbour E., Takahashi K., Wang X., et al. Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am. J. Hematol. 2013, 88(10):831-837.
5. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. New Engl. J. Med. 2011, 364(26):2496-2506.
6. Chen C.Y., Lin L.I., Tang J.L., et al. RUNX1 gene mutation in primary myelodysplastic syndrome-the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br. J. Haematol. 2007, 139(3):405-414.
7. Lai J.L., Preudhomme C., Zandecki M., et al. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoiesis and a high incidence of P53 mutations. Leukemia 1995, 9(3):370-381.
8. Shih L.Y., Huang C.F., Wang P.N., et al. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia 2004, 18(3):466-475.
9. Ding L., Ley T.J., Larson D.E., et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012, 481(7382):506-510.
10. Bejar R., Stevenson K.E., Caughey B.A., et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J. Clin. Oncol. 2012, 30(27):3376-3382.
11. Daver N., Strati P., Jabbour E., et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am. J. Hematol. 2013, 88(1):56-59.
12. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99(12):4326-4335.
13. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98(6):1752-1759.
14. Georgiou G., Karali V., Zouvelou C., et al. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance. Br. J. Haematol. 2006, 134(3):302-306.
15. Dicker F., Haferlach C., Sundermann J., et al. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML. Leukemia 2010, 24(8):1528-1532.
16. Takahashi K., Jabbour E., Wang X., et al. Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia 2013, 27(10):2081-2083.
17. Downward J., Targeting R.A.S. signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3(1):11-22.
18. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 1989, 49(17):4682-4689.
19. Coghlan D.W., Morley A.A., Matthews J.P., Bishop J.F. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. Leukemia 1994, 8(10):1682-1687.
20. Janssen J.W., Steenvoorden A.C., Lyons J., et al. RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc. Natl. Acad. Sci. U. S. A. 1987, 84(24):9228-9232.
21. Borthakur G., Popplewell L., Boyiadzis M., et al. Phase I/II trial of the MEK1/2 inhibitor trametinib (GSK 1120212) in relapsed/refractory myeloid malignancies: evidence of activity in patients with RAS mutation-positive disease. ASH Annu. Meeting Abstr. 2012.
22. Jain N., Curran E., Iyengar N.M., et al. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Clin. Cancer Res. 2014, 20(2):490-498.
23. Bacher U., Haferlach T., Kern W., Haferlach C., Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007, 92(6):744-752.
24. Horiike S., Misawa S., Nakai H., et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 1994, 8(8):1331-1336.
25. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
26. Lin P., Jones D., Medeiros L.J., Chen W., Vega-Vazquez F., Luthra R. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am. J. Clin. Pathol. 2006, 126(4):530-533.
27. Patel K.P., Ravandi F., Ma D., et al. Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am. J. Clin. Pathol. 2011, 135(1):35-45.
28. Luthra R., Patel K.P., Reddy N.G., et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica 2014, 99(3):465-473.
29. International Standing Committee on Human Cytogenetic N, Shaffer LG, Tommerup N. ISCN 2005: an international system for human cytogenetic nomenclature (2005): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel; Farmington, CT: Karger; 2005.
30. Voso M.T., Fenu S., Latagliata R., et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J. Clin. Oncol. 2013, 31(21):2671-2677.
31. Frohling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group ulm. Blood 2002, 100(13):4372-4380.
32. Ravandi F., Cortes J.E., Jones D., et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J. Clin. Oncol. 2010, 28(11):1856-1862.
33. DeZern A.E., Sung A., Kim S., et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133consecutive newly diagnosed patients from a single institution. Biol. Blood Marrow Transplant 2015, 17(9):1404-1409.
34. Al-Kali A., Quintas-Cardama A., Luthra R., et al. Prognostic impact of RAS mutations in patients with myelodysplastic syndrome. Am. J. Hematol. 2013, 88(5):365-369.
35. Kadia T.M., Kantarjian H., Kornblau S., et al. Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS. Cancer 2012, 118(22):5550-5559.
36. Jabbour E., Kantarjian H., Ravandi F., et al. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 2011, 117(6):1236-1244.
37. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92(7):2322-2333.